Mirum Pharmaceuticals, Inc.
MIRM
$71.97
$0.160.22%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.35% | 51.22% | 46.18% | 39.21% | 38.08% |
| Total Depreciation and Amortization | 26.01% | 60.82% | 118.21% | 262.41% | 326.08% |
| Total Amortization of Deferred Charges | 4.23% | 9.73% | 48.70% | 128.97% | 431.27% |
| Total Other Non-Cash Items | 9.91% | -46.85% | -55.14% | -41.77% | -43.98% |
| Change in Net Operating Assets | -230.50% | -209.93% | 241.29% | 203.18% | 173.44% |
| Cash from Operations | 138.39% | 81.47% | 114.55% | 98.62% | 75.70% |
| Capital Expenditure | 53.54% | -1,160.49% | -811.01% | -177.21% | -114.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 100.00% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 9.51% | -233.85% | -184.35% | -168.16% | -274.63% |
| Cash from Investing | 84.42% | 20.85% | 15.93% | -18.26% | -1,138.65% |
| Total Debt Issued | -- | -- | -- | -100.00% | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -88.86% | -89.25% | -92.21% | -93.64% | 102.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 99.86% | 99.86% |
| Cash from Financing | -88.85% | -92.96% | -94.74% | -95.77% | 1.86% |
| Foreign Exchange rate Adjustments | 1,034.27% | -70.67% | -875.19% | 221.79% | -254.35% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 92.32% | -159.05% | -140.04% | -147.62% | -144.90% |